A public-health-style resource for psychedelic-assisted therapy.

We publish guidance on treatment evidence, safety considerations, legal access, costs, insurance, care pathways, and provider evaluation for psychedelic-assisted therapies in Canada and the United States.

• Ketamine therapy, including off-label care models and esketamine/Spravato.
• Psilocybin-assisted therapy, including clinical trials and special access pathways.
• MDMA-assisted therapy, including investigational PTSD treatment context.
• Condition, population, insurance, training, location, and legal access guides.

The site is designed to feel like a trusted medical publication and care navigation resource, not a psychedelic culture site, wellness brand, or lead-generation directory.

We prioritize plain language, careful claims, jurisdiction-specific access details, and visible separation between editorial content and any future provider listings.

• Patients and families comparing options and preparing questions for licensed clinicians.
• Clinicians and referrers looking for concise evidence, safety, and regulatory context.
• Researchers, policy readers, and care navigators tracking access changes by jurisdiction.